Clinical Trial Update: QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating N-803 with haNK and Avelumab in Merkel cell carcinoma after checkpoint therapy was terminated, with results posted in August 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• N-803
• haNK (natural killer cell line)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Merkel Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-08-09